Global Macrolide Antibiotics Market is estimated to be US$ 118.1 Billion by 2030 with a CAGR of 11.5 (Business Opportunities - Marketing & Sales)

USAOnlineClassifieds > Business Opportunities > Marketing & Sales

Item ID 1569049 in Category: Business Opportunities - Marketing & Sales

Global Macrolide Antibiotics Market is estimated to be US$ 118.1 Billion by 2030 with a CAGR of 11.5


Free Online Advertising
Free Internet Web Site Advertising.


UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.


Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.

The Global Macrolide Antibiotics market accounted for US$ 39.7 billion in 2020 and is estimated to be US$ 118.1 billion by 2030 and is anticipated to register a CAGR of 11.5%. Antibiotics originating from Saccharopolyspora erythraea are known as macrolide antibiotics. Macrolide antibiotics have a wide range of action against many gram-positive bacteria and are bacteriostatic in nature. Soft tissue infections, respiratory infections, sexually transmitted infections, and atypical mycobacterial infections are all treated with macrolide antibiotics. Macrolide antibiotics have anti-inflammatory and immunomodulatory properties and are used to treat a variety of ailments. Macrolide antibiotics can be used as a first- or second-line therapy, depending on the situation. Erythromycin is used as a second-line treatment for allergies and is used as a first-line treatment for pertussis and other disorders.

The report " Global Macrolide antibiotics Market, By drug type (Azithromycin, erythromycin, telithromycin, calirithromycin and fidaxomycin), By Infection (legionella sp., mycoplasma pneumonia, peliosishepatis, bordetella pertussis and others), By Route of administration (oral and parenteral),By End-user, hospital, clinics, ambulatory center, research center and others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

Oritavancin, delbavancin, and televancin are three new Glycopepetide derivatives produced in response to the emergence of vancomycin-resistant strains. The FDA has approved televancin, but oritavancin and delbavancin are still in progress.
Analyst View:

The global demand for Macrolide Antibiotics is expected to expand in the coming years, owing to the rise in antibiotic use. The global macrolide antibiotics market is expected to develop rapidly during the forecast period, owing to rising macrolide demand around the world. The market is also expected to rise due to the rising prevalence of bacterial skin infections and the growing number of dermatology clinics. Furthermore, the macrolide drug market is being driven by a growing elderly population, an unprecedented rate of multi-strain resistant bacterial strains, and better benefits over traditional antibiotics.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Macrolide antibiotics Market, By drug type (Azithromycin, erythromycin, telithromycin, calirithromycin and fidaxomycin), By Infection (legionella sp., mycoplasma pneumonia, peliosishepatis, bordetella pertussis and others), By Route of administration (oral and parenteral),By End-user, hospital, clinics, ambulatory center, research center and others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Macrolide-antibiotics-Market-4689

Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : All Cities
Last Update : Nov 26, 2021 3:37 AM
Number of Views: 54
Item  Owner  : NileshDM
Contact Email:
Contact Phone: 7775049802

Friendly reminder: Click here to read some tips.
USAOnlineClassifieds > Business Opportunities > Marketing & Sales
 © 2022 USAOnlineClassifieds.com
2022-05-17 (0.398 sec)